Category: arteriosclerosis

Shire presents study findings on its ADHD treatments at psychiatric meeting Oct 29-30

October 29, 2009

HONOLULU -- October 29, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Defi

New drug may reduce heart attack damage

July 24, 2009

A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.

Vyvanse CII significantly improved ADHD symptoms for children 13 hours after administration

July 22, 2009

PHILADEPHIA -- July 22, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that a study published online in the peer-reviewed journal Child and Adolescent Psychiatry and Mental Health found once-daily Vyvanse® (lisdexamfetamine dimesylate) CII significantly reduced the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in chi

VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD

July 1, 2009

Hollywood, FL -- July 1, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced results from a Phase 3b study that found VYVANSE® (lisdexamfetamine dimesylate) CII demonstrated significant efficacy at 14 hours after administration during a simulated workplace environment study in adults with Attention Deficit Hyperactivity Disorder (ADHD).

Study finds carbon monoxide has therapeutic benefits

January 20, 2003

Exposing rats to low levels of carbon monoxide (CO) prior to aorta transplantation prevents arteriosclerosis associated with chronic organ rejection and can also suppress stenosis after balloon-angioplasty-induced carotid artery injury, according to a study published in the Feb. 1 edition of Nature Medicine. The article is published online today.
"These findings demonstrate a significant protective role for CO in vascular injury and support its use as a therapeutic agent," according to study author Leo Otterbein, Ph.D., research assistant professor, University of Pittsburgh School of Medicine, division of pulmonary and critical care medicine.